NASHUA, N.H.
iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that UltraMed Technology Corporation, the Company’s partner in Taiwan, has purchased a third Xoft® Axxent® Electronic Brachytherapy System®. With this agreement, Intraoperative Radiation Therapy (IORT) with the Xoft System is now available in nine Taiwanese hospitals, helping meet the growing demand for IORT in the country.
“Xoft began our relationship with UltraMed Technology Corporation three years ago, with the goal of expanding our IORT global footprint,” said Ken Ferry, President and CEO of iCAD, Inc. “Since that time, the partnership has grown and we hope to build on the momentum we have established with the UltraMed team to increase patient access to our IORT solution in Taiwan and in other Asian markets.”
IORT is delivered at the time of a breast cancer surgery in just one dose. After the breast surgeon performs a lumpectomy, or removal of the early-stage breast cancer tumor, radiation is targeted directly into the tumor cavity, to kill any remaining cancer cells. Because the radiation is administered in such a targeted manner, it minimizes the radiation to surrounding healthy tissue and organs. IORT eliminates the logistically impractical five-to-seven week daily regimen of traditional whole breast radiation therapy. In most cases, patients are able to go home the same day and do not have to return for follow up treatments.
The Xoft System is a mobile and flexible therapy option that can dramatically reduce treatment times compared to whole breast radiation therapy for the treatment of early-stage breast cancer. When used for IORT, the Xoft System delivers a single, prescribed, targeted dose of isotope-free radiation eliminating the need for a shielded treatment environment.
“The incidence of breast cancer in Taiwan is amongst the highest in all of Asia and is the most prevalent form of cancer in Taiwanese women,” said Tony Kuo, CEO of UltraMed Technology Corporation. “Being able to provide customers cutting-edge technology including the Xoft System helps them offer more treatment options to their patients.”
To learn more about the Xoft System visit UltraMed Technology Corporation’s booth at Changhua Christian Hospital’s International Breast Cancer Conference July 7, 2014 at Changhua Christian Hospital in Changhua City, Taiwan.
About Xoft Axxent Electronic Brachytherapy System
The Xoft Axxent System is an isotope-free radiation treatment cleared by the U.S. Food and Drug Administration and CE marked in the EU for use anywhere in the body, including for the treatment of early-stage breast cancer, gynecological cancers and non-melanoma skin cancer. It utilizes a proprietary miniaturized x-ray as the radiation source that delivers precise treatment directly to cancerous areas while sparing healthy tissue and organs. The Xoft System requires only minimal shielding and therefore does not require room redesign or construction investment. Minimal shielding also allows medical personnel to remain in the room with the patient during treatment. The mobility of the Xoft System makes it easy to treat patients at multiple locations and to easily store the system when not in use. Xoft is a wholly owned subsidiary of iCAD, Inc. For more information about Xoft visit www.xoftinc.com, like us on Facebook or follow us on Twitter at @xofticad.
About UltraMed Technology Corporation
UltraMed Technology Corporation’s management team has more than 160 years experience in the medical industry, and keeps very good relationships with key opinion leaders in these fields, especially in the treatment of cancer. The Xoft Axxent System has been approved by Taiwan FDA for use anywhere in the body, including early-stage breast cancer, gynecological cancers and non-melanoma skin cancer. Currently the Xoft Axxent System is the leading product for the treatment of early-stage breast cancer with IORT in Taiwan and has entered into a growth stage. Tony Kuo has joined the company as Chief Executive Officer and has over 40 years of experience in the medical and pharmaceutical industry, including sales and marketing experience in oncology. For more information, please visit www.ultramed-tech.com.tw.
About iCAD, Inc.
iCAD is an industry-leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. iCAD offers a comprehensive range of high-performance, upgradeable CAD solutions for mammography and advanced image analysis and workflow solutions for Magnetic Resonance Imaging, for breast and prostate cancers and Computed Tomography for colorectal cancer. iCAD’s Xoft® Axxent® Electronic Brachytherapy (eBx®) System®, offers radiation treatment for early-stage breast cancer that can be administered in the form of intraoperative radiation therapy or accelerated partial breast irradiation. The Xoft System is also cleared for the treatment of non-melanoma skin cancer and gynecological cancers. For more information, call 877-iCADnow, or visit www.icadmed.com.
“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to the Company’s ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “will”, “continue”, “anticipate”, “likely”, “seek”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.
CONTACT
For iCAD investor relations
LHA
Anne Marie Fields,
212-838-3777 x6604
afields@lhai.com
or
For
iCAD media inquiries
MSLGROUP
Wendy Ryan, 781-684-0770
iCAD@mslgroup.com
